HGH (recombinant GH) supplies exogenous GH directly (bypassing hypothalamic/pituitary control), producing higher circulating GH levels but without restoring physiological pulsatility
JAMA Internal Medicine, 184 (12), 1443
These cardiometabolic improvements matter because excess weight drives many of these risk factors
Generally, individuals eligible for semaglutide typically have a body mass index (BMI) of 27 or higher and at least one weight-related condition
Scientifically, aging reduces MC4R sensitivity and -MSH production, exacerbating HSDD, but activating these pathways can reverse the trend, with studies showing PT-141 boosts desire scores by up to 51% in affected women.[1][2] This is crucial post-40, as estrogen decline compounds neurological changes, leading to GSM and reduced dopamine release in reward centers
Most active users also expect short-term treatment: 69% have used GLP-1 weight loss medications for fewer than two years, and over half plan to stop within two more years